Chapter 65
Noonan Syndrome and PTPN11 Mutations
Marco Tartaglia,
Bruce D. Gelb,
Marco Tartaglia
Search for more papers by this authorBruce D. Gelb
Search for more papers by this authorMarco Tartaglia,
Bruce D. Gelb,
Marco Tartaglia
Search for more papers by this authorBruce D. Gelb
Search for more papers by this authorBook Editor(s):Michael Artman MD, D. Woodrow Benson MD, PhD,
Deepak Srivastava MD,
Makoto Nakazawa MD,
D. Woodrow Benson MD, PhD
Professor of Pediatrics, Director, Cardiovascular Genetics, Division of Cardiology, Cincinnati Children's Hospital Medical Center
Search for more papers by this authorDeepak Srivastava MD
Pogue Distinguished Chair in Research on Cardiac Birth Defects, Joel B. Steinberg, M.D. Chair in Pediatrics Professor, Departments of Pediatrics and Molecular Biology, University of Texas, Southwestern Medical Center at Dallas
Search for more papers by this authorMakoto Nakazawa MD
Professor and Head, Pediatric Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University
Search for more papers by this authorFirst published: 01 January 2005
Summary
This chapter contains sections titled:
-
Genetic mapping and disease gene discovery
-
PTPN11 and IT protein product, SHP-2
-
Molecular pathology of Noonan syndrome
-
Genotype/phenotype correlation
References
- Noonan J, Ehmke D. Associated non cardiac malformations in children with congenital heart disease. J Pediatr 1963; 63: 468–70.
- Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 1968; 116: 373–80.
- Opitz JM. The Noonan syndrome. Am J Med Genet 1985; 21 : 515–18.
- Sharland M, Taylor R, Patton MA, Jeffery S. Absence of linkage of Noonan syndrome to the neurofibromatosis type 1 locus. J Med Genet 1992; 29: 188–90.
- Flintoff WF, Bahuau M, Lyonnet S, et al. No evidence for linkage to the type 1 or type 2 neurofibromatosis loci in Noonan syndrome families. Am J Med Genet 1993; 46: 700–5.
- Jamieson CR, van der Burgt I, Brady AF, et al. Mapping a gene for Noonan syndrome to the long arm of chromosome 12. Nat Genet 1994; 8: 357–60.
- Legius E, Schollen E, Matthijs G, Fryns JP. Fine mapping of Noonan/cardio-facio cutaneous syndrome in a large family. Eur J Hum Genet 1998; 6: 32–7.
- Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29: 465–8.
- Chen B, Bronson RT, Klaman LD, et al. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet 2000; 24: 296–9.
- Ahmad S, Banville D, Zhao Z, Fischer EH, Shen SH. A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains. Proc Natl Acad Sci USA 1993; 90: 2197–201.
- Reeves SA, Ueki K, Sinha B, Difiglia M, Louis DN. Regional expression and subcellular localization of the tyrosine-specific phosphatase SH-PTP2 in the adult human nervous system. Neuroscience 1996; 71: 1037–42.
- Feng GS, Hui CC, Pawson T. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science 1993; 259: 1607–11.
- Arrandale JM, Gore-Willse A, Rocks S, et al. Insulin signaling in mice expressing reduced levels of Syp. J Biol Chem 1996; 271: 21353–8.
- Saxton TM, Henkemeyer M, Gasca S, et al. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. Embo J 1997; 16: 2352–64.
- Qu CK, Yu WM, Azzarelli B, et al. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol Cell Biol 1998; 18: 6075–82.
- Saxton TM, Ciruna BG, Holmyard D, et al. The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat Genet 2000; 24: 420–3.
- Perkins LA, Larsen I, Perrimon N. Corkscrew encodes a putative protein tyrosine phosphatase that functions to transduce the terminal signal from the receptor tyrosine kinase torso. Cell 1992; 70: 225–36.
- Lu X, Perkins LA, Perrimon N. The torso pathway in Drosophila: a model system to study receptor tyrosine kinase signal transduction. Development 1993; Suppl.: 47–56.
- Perrimon N, Lu X, Hou XS, et al. Dissection of the Torso signal transduction pathway in Drosophila. Mol Reprod Dev 1995; 42: 515–22.
- Cleghon V, Feldmann P, Ghiglione C, et al. Opposing actions of CSW and RasGAP modulate the strength of Torso RTK signaling in the Drosophila terminal pathway. Mol Cell 1998; 2: 719–27.
- Ghiglione C, Perrimon N, Perkins LA. Quantitative variations in the level of MAPK activity control patterning of the embryonic termini in Drosophila. Dev Biol 1999; 205: 181–93.
- Perkins LA, Johnson MR, Melnick MB, Perrimon N. The nonreceptor protein tyrosine phosphatase corkscrew functions in multiple receptor tyrosine kinase pathways in Drosophila. Dev Biol 1996; 180: 63–81.
- Lorenzen JA, Baker SE, Denhez F, et al. Nuclear import of activated D-ERK by DIM-7, an importin family member encoded by the gene moleskin. Development 2001; 128: 1403–14.
- Raabe T. The sevenless signaling pathway: variations of a common theme. Biochim Biophys Acta 2000; 1496: 151–63.
- Allard JD, Chang HC, Herbst R, McNeill H, Simon MA. The SH2-containing tyrosine phosphatase corkscrew is required during signaling by sevenless, Ras1 and Raf. Development 1996; 122: 1137–46.
- Herbst R, Carroll PM, Allard JD, Schilling J, Raabe T, Simon MA. Daughter of sevenless is a substrate of the phosphotyrosine phosphatase Corkscrew and functions during sevenless signaling. Cell 1996; 85: 899–909.
- Herbst R, Zhang X, Qin J, Simon MA. Recruitment of the protein tyrosine phosphatase CSW by DOS is an essential step during signaling by the sevenless receptor tyrosine kinase. Embo J 1999; 18: 6950–61.
- Firth L, Manchester J, Lorenzen JA, Baron M, Perkins LA. Identification of genomic regions that interact with a viable allele of the Drosophila protein tyrosine phosphatase corkscrew. Genetics 2000; 156: 733–48.
- Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002; 70: 1555–63.
- Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92: 441–50.
- Huyer G, Ramachandran C. The specificity of the N-terminal SH2 domain of SHP-2 is modified by a single point mutation. Biochemistry 1998; 37: 2741–7.
- Lee CH, Kominos D, Jacques S, et al. Crystal structures of peptide complexes of the aminoterminal SH2 domain of the Syp tyrosine phosphatase. Structure 1994; 2: 423–38.
- Allen M. Tildesley. Computer Simulation of Liquids. Oxford: Clarendon, 1987.
- Noguti T, Go N. Efficient Monte Carlo method for simulation of fluctuating conformations of native proteins. Biopolymers 1985; 24: 527–46.
- O'Reilly AM, Pluskey S, Shoelson SE, Neel BG. Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol Cell Biol 2000; 20: 299–311.
-
Bertola DR,
Kim CA,
Pereira AC, et al.
Are Noonan syndrome and Noonan-like/multiple giant cell lesion syndrome distinct entities?
Am J Med Genet
2001;
98: 230–4.
10.1002/1096-8628(20010122)98:3<230::AID-AJMG1080>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- Digilio MC, Conti E, Sarkozy A, et al. Grouping of Multiple-Lentigines/LEOPARD and Noonan Syndromes on the PTPN11 Gene. Am J Hum Genet 2002; 71: 389–94.
- Kavamura MI, Pomponi MG, Zollino M, et al. PTPN11 mutations are not responsible for the Cardiofaciocutaneous (CFC) syndrome. Eur J Hum Genet 2003; 11: 64–8.
- Ion A, Tartaglia M, Song X, et al. Absence of PTPN11 mutations in 28 cases of cardiofaciocutaneous (CFC) syndrome. Hum Genet 2002; 111: 421–7.
- Tartaglia M, Cotter PD, Zampino G, Gelb BD, Rauen KA. Exclusion of PTPN11 mutations in Costello syndrome: further evidence for distinct genetic etiologies of Noonan, cardiofaciocutaneous, and Costello syndromes. Clin Genet 2003; 63: 423–6.
